Clinical Evaluations of The Efficacy of Polisorb In The Complex Therapy of Acute Intestinal Infections
Acute intestinal infections (AII) are very prominent in infectious pathology and are characterized by a high incidence and frequent development of post-infectious disorders.
The problems associated with the reduction in the burden of acute intestinal infections and improving the outcome of their treatment are still relevant at the present time. Thus, adequately prescribed etiotropic and/or pathogenetic therapy can affect both the outcome and the duration of the disease.
Patients and methods:
Under our supervision, there were 97 patients with acute intestinal infections aged from 18 to 84 years, who were treated in the first infectious disease unit of the Municipal health care institution City hospital No. 5 in Barnaul. The vast majority of patients were admitted to the hospital in the first three days of the disease. Moderate and severe forms of the disease prevailed amongst all hospital patients - in 52 patients (53.6%) and a mild course of the disease was observed in 45 patients (46.4%). Clinical monitoring of patients was carried out daily from the moment of their admission to the hospital and until their discharge. In addition, all patients underwent general clinical research, coprological and bacteriological examination and serum diagnosis (HAI with salmonella and dysenteric antigens). The etiological deciphering of the diagnosis took place in 16.5% of cases. Salmonellosis caused by Salmonella enteritidis prevailed in 43.75% of cases among the deciphered diseases. Unspecified intestinal infections occurred in 81 patients (83.5% of cases). The patients were divided into 2 groups by random sampling technique and matched by sex, age and presence of concomitant somatic pathology. The main group "A" included 42 patients who received, along with etiotropic therapy (33 people), as part of a complex pathogenetic therapy (detoxification and rehydration therapy, enzyme preparations, pre- and probiotics), the medication "Polisorb MP" in a therapy dosage of 100-200 mg/kg of body weight per day (average dose - 2 grams 4 times a day). The course of the medication ranged from 2 to 7 days (an average of 3-5 days). The control group "B" included 52 patients, who received both etiotropic (43 patients) and pathogenetic therapy, with the exception of enterosorbents (Polisorb MP).
According to the severity of the course of the disease, moderate and severe forms prevailed in group "A" (moderate severity in 23 patients, severe in 2), in group "B" moderately severe courses of the disease were also observed (in 28 patients). Concomitant somatic pathology occurred in 14 patients of the main group (patients with chronic or acute non-infectious pathology of gastrointestinal tract, severe secondary immunodeficiencies, and oncology diseases were excluded from the research) and in 14 patients of the control group. Pathological admixtures in the bowel movement in patients of both groups were met with the same frequency (16% in group "A" and 17% in group "B"). Parenteral detoxification/rehydration therapy was prescribed (taking into account the peculiarities of the clinical course of the disease) to 24 patients of the main group and 26 patients of the control group. At the same time, the average duration of intravenous infusion was about 2.4 days in both groups. The duration of the conducted antimicrobial therapy ranged from 2 to 10 days and averaged 4.8 days in the main group and 5.2 days in the control group. It is important to note that the rapid recovery of body temperature in the study group (33 patients had fever). In the course of the treatment with Polisorb MP, the average number of days of fever was 1.7 days versus 2.3 days in the control group (40 patients had fever). It is also important to mention a more rapid disappearance of symptoms of gastric indigestion and a more rapid recovery of bowel movement consistency in group "A" (3.9 days of diarrhea); 4.1 days of diarrhea in group "B". The average hospitalization period was 6.7 patient days in the main group and 7.7 patient days in the control group. Moreover, by the time of discharge, residual effects occurred only in 2 patients from both groups: one patient retained a loose bowel movement (unauthorized leave from the department), and 1 patient retained a small admixture of mucus in the bowel movement.
Our research has shown that the use of the enterosorbent "Polisorb MP" in the treatment of acute intestinal infections is characterized by high clinical efficacy. Thus, the use of Polisorb MP in the complex therapy of patients with AII leads to a decrease in the duration of symptoms of intoxication and diarrheal syndrome, helps to reduce the duration of antimicrobial therapy, and also reduces the hospitalization period, which is undoubtedly significant in the treatment of this patient population. The medication "Polisorb MP" can be recommended in the comprehensive treatment of patients with acute intestinal infections.
Witness: Deputy Chief Doctor /Signed/
/Sealed: Health care Committee of Barnaul city Administration
Municipal health care institution “City hospital No. 5” * OGRN 1022201767191/